HOME > TOP STORIES

TOP STORIES

BUSINESS Drug Makers Scratching Heads to Meet Daily Rep Report Requirements for New Detailing Guidelines

April 10, 2019
ORGANIZATION Vaccine Heavyweight Prods Japan to Expedite Recommendation Process for Immunization Program, Ensure Funding

April 9, 2019
REGULATORY Sakigake Status Granted to Takeda’s Narcolepsy Med, Ninlaro, Daiichi Sankyo’s Valemetostat and More

April 9, 2019
BUSINESS Oncolys, Chugai Ink 50 Billion Yen Licensing Pact for Telomelysin

April 9, 2019
BUSINESS Novartis’ Eylea Challenger Could Reach Filing This Year for 2020 Launch

April 8, 2019
REGULATORY Japan’s 1st Avastin Biosimilar Could Get Listing as Early as November; Lilly’s EGFR Up for MHLW Panel Review

April 8, 2019
INTERVIEW With 90% Premium Cut, Japanese CEA Scheme Goes Beyond Its Purpose of Being “Complementary” Tool: FPMAJ Pricing Chief

April 5, 2019
BUSINESS Lilly Japan Nets 263 Billion Yen in 2018, Now 6th in Sales Ranking

April 4, 2019
BUSINESS Cefazolin Generic Shortage Raises Worries of Supply Crunch after G1 LLP Withdrawals

April 4, 2019
INTERVIEW Ex-Minister Tamura: 3 New Sources of Social Security Funding Needed to Stem Overreliance on Drug Price Cuts

April 3, 2019
COMMENTARY Building Credible, Convincing System Holds Key for Japan’s Cost-Effectiveness Assessment

April 2, 2019
REGULATORY MHLW Reveals Details of New Withdrawal Rules for Off-Patent Branded Drugs

April 1, 2019
BUSINESS Daiichi Sankyo Bags US$6.9 Billion AstraZeneca Pact for Cancer Hopeful DS-8201, Announces CEO Change

April 1, 2019
INTERVIEW Kyokai Kenpo Director Yoshimori: Japan Should Eventually Use Cost-Effectiveness Assessment to Set Launch Prices

March 29, 2019
BUSINESS Sumitomo Dainippon Carves Out Pain Program, 2025 Launch Eyed for Rare Pediatric Disease

March 29, 2019
REGULATORY Opdivo Up for Yet Another Re-Pricing after CEA Confirmatory Analysis, but New Price Undisclosed

March 28, 2019
REGULATORY National Cancer Center’s Fujiwara Named New PMDA Chief

March 27, 2019
BUSINESS Kymriah OK’ed, Novartis Says It’s Not Up for Outcome-Based Pricing in Japan

March 27, 2019
BUSINESS Novartis Snags Japan Approval for CAR-T Therapy Kymriah

March 26, 2019
REGULATORY Nesp Biosame Likely to Be Priced at 70% of Originator as Stopgap Measure

March 26, 2019

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch

By Ken Yoshino

Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…